Protalix BioTherapeutics Reports Q2 2026 Financial Results

What Happened
Protalix BioTherapeutics, Inc. announced its financial results for the fiscal quarter ended June 30, 2026 and provided a business and clinical update via a press release. The company furnished the press release as Exhibit 99.1 to a Form 8-K filed on August 12, 2026; the report was signed by President and CEO Dror Bashan.

Key Details

• Filing date: August 12, 2026 (Form 8-K, Item 2.02: Results of Operations and Financial Condition).
• Period covered: fiscal quarter ended June 30, 2026.
• Press release: furnished as Exhibit 99.1 (contains the financial results and business/clinical update).
• Legal note: per General Instruction B.2, the press release is furnished (not “filed”) and is not automatically incorporated by reference into registration statements.

Why It Matters
This filing signals that Protalix has released its latest quarterly earnings and operational update; investors should read the Exhibit 99.1 press release for key numbers (revenue, profit/loss, cash position) and clinical milestones that can affect the company’s outlook and stock performance. The filing’s legal note means the press release is provided for disclosure but is not treated as a filed document for certain securities-law liabilities or automatic incorporation into other filings.